Frazier Life Sciences Management, L.P. Cytokinetics Inc Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q2 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 554,731 shares of CYTK stock, worth $31.6 Million. This represents 0.97% of its overall portfolio holdings.
Number of Shares
554,731Holding current value
$31.6 Million% of portfolio
0.97%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
370Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$836 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$683 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$446 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$363 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.36B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...